{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T06:18:49Z","timestamp":1725776329478},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00105-004-0889-y","type":"journal-article","created":{"date-parts":[[2005,1,20]],"date-time":"2005-01-20T17:39:49Z","timestamp":1106242789000},"page":"47-50","source":"Crossref","is-referenced-by-count":3,"title":["Therapierefrakt\u00e4re kutane nekrotisierende Vaskulitis","Refractory cutaneous necrotizing vasculitis"],"prefix":"10.1007","volume":"57","author":[{"given":"H.","family":"Seybold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"L\u00fcftl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"889_CR1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"Fauci","year":"1983","unstructured":"Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76\u201385","journal-title":"Ann Intern Med"},{"key":"889_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1067\/mjd.2003.212","volume":"48","author":"Fiorentino","year":"2003","unstructured":"Fiorentino DF (2003) Cutaneous vasculitis. J Am Acad Dermatol 48: 311\u2013340","journal-title":"J Am Acad Dermatol"},{"key":"889_CR3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0190-9622(87)70100-5","volume":"16","author":"Fredenberg","year":"1987","unstructured":"Fredenberg MF, Malkinson FD (1987) Sulfone therapy in the treatment of leukocytoclastic vasculitis. J Am Acad Dermatol 16: 772\u2013778","journal-title":"J Am Acad Dermatol"},{"key":"889_CR4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1365-2133.1998.02440.x","volume":"139","author":"Fukuhara","year":"2000","unstructured":"Fukuhara K, Urano Y, Kimura S, Hori K, Arase S (2000) Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 139: 556\u2013558","journal-title":"Br J Dermatol"},{"key":"889_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2133.2000.03673.x","volume":"143","author":"Grabbe","year":"2000","unstructured":"Grabbe J, Haas N, Moller A, Henz BM (2000) Erythema elevatum et diutinum\u2014evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol 143: 415\u2013420","journal-title":"Br J Dermatol"},{"key":"889_CR6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","volume":"33","author":"Hunder","year":"1990","unstructured":"Hunder GG, Arend WP, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 1065\u20131067","journal-title":"Arthritis Rheum"},{"key":"889_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"Jennette","year":"1994","unstructured":"Jennette JC, Falk RJ, Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187\u2013192","journal-title":"Arthritis Rheum"},{"key":"889_CR8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2340\/00015555755456","volume":"75","author":"N","year":"1995","unstructured":"N\u00fcrnberg W, Grabbe J, Czarnetzki BM (1995) Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol 75: 54\u201356","journal-title":"Acta Derm Venereol"},{"key":"889_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","volume":"29","author":"Sharquie","year":"2002","unstructured":"Sharquie KE, Najim RA, Abu-Raghif AR (2002) Dapsone in Behcet\u2019s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29: 267\u2013279","journal-title":"J Dermatol"},{"key":"889_CR10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543784.10.7.1279","volume":"10","author":"Thomas-Golbanov","year":"2001","unstructured":"Thomas-Golbanov C, Sridharan S (2001) Novel therapies in vasculitis. Expert Opin Invest Drugs 10: 1279\u20131289","journal-title":"Expert Opin Invest Drugs"},{"key":"889_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/1523-1747.ep12471811","volume":"100","author":"Thuong-Nguyen","year":"1993","unstructured":"Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ (1993) Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 100: 349\u2013355","journal-title":"J Invest Dermatol"},{"key":"889_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2340\/00015555746364","volume":"74","author":"Van","year":"1994","unstructured":"Van de Kerkhof PC (1994) On the efficacy of dapsone in granuloma faciale. Acta Derm Venereol 74: 61\u201362","journal-title":"Acta Derm Venereol"},{"key":"889_CR13","unstructured":"Wozel G (1996) Dapson\u2014Pharmakologie, Wirkmechanismus und klinischer Einsatz. Thieme, Stuttgart New York, S\u00a024\u201348"},{"key":"889_CR14","doi-asserted-by":"crossref","unstructured":"Wozel G, Blasum C, Winter C, Gerlach B (1997) Dapsone hydroxylamine inhibits the LTB-4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Inflamm Res. 46: 420\u2013422","DOI":"10.1007\/s000110050215"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-004-0889-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-004-0889-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-004-0889-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T22:26:10Z","timestamp":1705789570000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-004-0889-y"}},"subtitle":["Erfolgreiche Sulfontherapie","Successful sulfone therapy"],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1007\/s00105-004-0889-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}